Clinical aspects of hepatocellular carcinoma in Japan

Area of Science:

• Hepatology
• Oncology
• Viral Hepatitis Research

Background:

• Hepatocellular carcinoma (HCC) exhibits distinct epidemiological profiles in Japan compared to other Asian nations.
• Japanese HCC patients are predominantly over 60 years old and positive for Hepatitis C Virus (HCV).
• Conversely, Hepatitis B Virus (HBV)-positive HCC is more common in younger individuals in other Asian countries.

Purpose of the Study:

• To highlight the unique characteristics of HCC in Japan.
• To outline current diagnostic and therapeutic strategies for HCC.
• To discuss the role of chemoprevention in HCC management.

Main Methods:

• Review of diagnostic imaging techniques including ultrasonography, dynamic CT, MRI, and CT angiography for early HCC detection.
• Analysis of treatment outcomes based on tumor size and liver function: surgical/ablation therapy for small HCC (<3 cm), transarterial chemoembolization (TACE) for larger tumors, and intra-arterial chemotherapy for advanced stages.
• Exploration of chemoprevention strategies, particularly HCV eradication via antiviral agents.

Main Results:

• Early detection of HCC (<3 cm) with preserved liver function allows for treatments yielding >60% 5-year survival.
• Established treatments for larger or advanced HCC include TACE and intra-arterial chemotherapy, though efficacy for the latter requires further evaluation.
• HCV eradication through antiviral therapy is a proven method to prevent hepatocarcinogenesis, with ongoing chemoprevention trials in Japan.

Conclusions:

• HCC in Japan presents unique demographic and etiological features, primarily linked to HCV in an aging population.
• A multimodal approach combining early diagnosis, tailored treatments, and chemoprevention is crucial for managing HCC.
• Further research into advanced HCC treatments and preventative strategies, including ongoing trials, is essential.